Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial
- First Online:
- 134 Downloads
The involvement of the central cholinergic system in alcohol abuse behavior is well known. It is possible that the reinforcing effects of ethanol are partially mediated by nicotinic receptors, which modulate neurotransmitter release. It was demonstrated that the application of a cholinesterase inhibitor reduces alcohol consumption in alcohol-preferring rats. This suggests that galantamine (GAL), a cholinesterase inhibitor, could be effective when seeking to prolong abstinence in recently detoxified alcoholics. This study represents the first reported clinical trial of a cholinergic drug in alcohol-relapse prevention.
Patients and methods
We investigated the efficacy and safety of GAL by conducting a 24-week randomized, placebo-controlled, multicentric clinical trial on 149 recently detoxified alcoholics. Survival analyses (Kaplan–Meier) were performed to reveal evidence of prolonged abstinence periods in patients who received GAL.
Our findings did not support our hypothesis. GAL did not extend the time to first severe relapse. However, additional post hoc analyses suggest that relapsed patients treated with GAL consume less ethanol per drinking day than patients treated with placebo.
GAL seems to be ineffective when used in relapse prevention of detoxified alcoholics. It is possible that alcohol needs to be “on board” for GAL to be beneficial. This could explain why our post hoc analysis showed that GAL possibly reduces the alcohol consumption of relapsers. If confirmed, GAL could play a role in the reduction of harmful alcohol use and at-risk consumption.
KeywordsGalantamine Alcohol dependence Harmful use Relapse prevention Cholinergic system
- Franke GH (1995) SCL-90-R. Die Symptom-Checkliste von Derogatis—Deutsche Version. Beltz Test, GöttingenGoogle Scholar
- Gsellhofer B, Fahrner EM, Platt J (1994) German version of the ‘European Addiction Severity Index’ (EuropASI). IFT Institut für Therapieforschung, MunichGoogle Scholar
- Iliev A, Traykov V, Prodanov D, Mantchev G, Yakimova K, Krushkov I, Boyadjieva N (1999) Effect of the acetylcholinesterase inhibitor galantamine on learning and memory in prolonged alcohol intake rat model of acetylcholine deficit. Methods Find Exp Clin Pharmacol 21(4):297–301PubMedCrossRefGoogle Scholar
- Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kampf P, Stracke R, Baehr M, Naber D, Wiedemann K (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60:92–99PubMedCrossRefGoogle Scholar
- Mann K, Ackermann K (2000) OCDS-G: psychometric values of the German version of the Obsessive Compulsive Drinking Scale. Sucht 46:90–100Google Scholar
- Nestby P, Vanderschuren LJ, De Vries TJ, Mulder AH, Wardeh G, Hogenboom F, Schoffelmeer AN (1999) Unrestricted free-choice ethanol self-administration in rats causes long-term neuroadaptations in the nucleus accumbens and caudate putamen. Psychopharmacology (Berl) 141(3):307–314CrossRefGoogle Scholar
- Rotermund C (1996) Investigator’s brochure galantamine. HF Arzneimittelforschung GmbH, WerneGoogle Scholar
- Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lubbert H, Albuquerque EX, Maelicke A (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305:1024–1036PubMedCrossRefGoogle Scholar